Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).
The transaction transfers ownership of the brand portfolio, comprised of Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The transaction is is expected to close on April 1.
The Pinsent Masons team was jointly led by partners Allistair Booth and Thilo Schneider and included senior associate Ciaran Wilkinson.
Commenting on the transaction Thilo Schneider said: “I am so pleased that we have been able to support Teva and to have brought this transaction to a successful conclusion. The sale is significant for both parties and we are proud to have achieved a successful outcome for Teva. We worked closely with them to understand what they wanted to achieve and helped to determine the best options available to them.”